Pharma.ai 2026:
The Q3 Platform Updates
Generative AI Software for Drug Discovery, Scientific Research & Sustainability
SOFTWARE FOR SCIENCE
THERAPEUTIC PIPELINE
High-Quality Therapeutic Programs Discovered Using Generative AI and Automation
Biology42
- PandaOmics Discover and prioritize novel targets
- Generative Biologics Discover and optimize novel biomolecules
- Life Star 2 Automated lab operating environment
Medicine42
Science42
- DORA Multi-agent generative research assistant
- Environmental Sustainability Generative AI technologies for environmental sustainability
- Data Warehouse Seamless cross-application data flow via efficient integration & standardization
Chemistry42
- Generative Chemistry Generate novel molecules
- Alchemistry Physics-based relative binding free energy engine
- ADMET & Off-target On-the-fly optimization
- MDFlow End-to-end simulation workflows
- Retrosynthesis Predict synthetic routes for molecular structures
- Model Training Train a state-of-the-art model on the data
- MolSpace Visualize the result of generations using GTM and compare it with public data
- Nach01 Multimodal natural & chemical languages foundation model
PSI Frontier
- Science MMAI Gym Boost the foundation model's intelligence in drug discovery and development
- Models Frontier SOTA models for Pharma
- DDD Benchmark Evaluating model capability across drug discovery and development process
- ScienceAI Bench Broader scientific reasoning across biology, chemistry & longevity
- MCPs Model Context Protocol servers exposing Pharma.AI tools to agents
- Skills + Agents Agentic workflows & reusable skills built on the Pharma.AI stack
Indication
TARGET ID
HIT TO LEAD
LEAD OPT.
IND-ENABLING
PHASE I
PHASE II
PHASE III
Idiopathic Pulmonary Fibrosis
IPF Inhalable
BRCA-mutated Cancer
Out-licensed to Exelixis
Immuno-Oncology
ER+/HER2- Breast Cancer
Out-licensed to Menarini
Solid Tumors
Out-licensed to Menarini
Inflammatory Bowel Disease
Anemia of Chronic Kidney Disease
Greater China Rights Out‑licensed to TaiGen
MTAP-/- Cancer
Solid Tumors
Solid Tumors
CNS
Co-development with Hygtia Therapeutics
Inflammatory Diseases
Obesity & Metabolic Diseases
Out-licensed to undisclosed partner
Pain
Greater China rights out-licensed to undisclosed partner
Pain
Immuno-Oncology
Solid Tumors
Obesity & Metabolic Diseases
KRAS-driven Solid Tumors
Metabolic Disease and Oncology
Ocular Diseases
Inflammatory Diseases
Obesity & Metabolic Diseases
More programs in discovery
Available for Licensing
Interested in learning more about Pharma.ai?
Contact Us
Insilico Medicine 2-page overview
Download
How Early Protein Modeling Advanced to AI-Driven Drug Discovery with Insilico Medicine
In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding.
Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules.
Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules.
Press Releases
Media Coverage
Publications
Most innovative biotechnology company in the world 2024
TNIK
TNIK Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
TEAD
Pan-TEAD Inhibitor: Treating Mesothelioma, and Solid Tumors
ENPP1
Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor: Treating anti-PD-1/-L1 resistant cancers
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
DGKA
Diacylglycerol kinase A (DGKA) Inhibitor: Treating solid tumors in combination with checkpoint inhibitor
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitor: Treating Tumors by Induction of BRCAness
FGFR2/3
FGFR2/3 Dual Inhibitor: Treatment of Solid Tumors
KIF18A
KIF18A Inhibitor: Treating chromosomally unstable cancers with TP53 mutations
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
